Lilly To Build $6B Pharmaceutical Manufacturing Facility In Alabama
Eli Lilly and Company announced Tuesday, Dec. 9 plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Ala.
Read MoreTag Archives: eli lilly and co
Lilly, IU Expanding Clinical Trial Access, Latest Treatments For Hoosiers
A new agreement under which Eli Lilly and Company will provide up to $40 million to Indiana University aims to expand access to clinical trials in Indiana, giving patients a pathway to Lilly’s latest investigational and innovative medicines while surrounding them with exceptional care.
Read More
Lilly Announces Changing The Thread Collection Campaign
Eli Lilly and Co. has launched a national campaign aimed at reducing the stigma surrounding obesity, using personal stories and visual symbolism to highlight the challenges faced by people living with the disease.
Read More
Lilly To Offer Direct-To-Employer Programs
Eli Lilly and Co. is preparing a new direct-to-employer model that will allow companies to offer coverage for its obesity medications, including Zepbound, beginning in early 2026.
Read MoreEli Lilly Becomes First Pharmaceutical To Hit $1 Trillion Valuation
Eli Lilly and Co. on Friday, Nov. 21 became the first health care company to surpass a $1 trillion market valuation, driven by intense investor demand for its fast-growing weight-loss drug portfolio.
Read More
Roche To Launch Blood-Based Alzheimer Test For Primary Care
Roche Diagnostics in Indianapolis is preparing to introduce what it says will be the first blood-based test for Alzheimer disease designed for use in primary care.
Read MoreTexas AG Accuses Lilly Of Offering Providers Illegal Incentives
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its most profitable drugs, including the high-demand GLP-1 medications Mounjaro and Zepbound that are used for weight loss and diabetes treatment.
Read MoreLilly Shares Slide Following Weight Loss Pill Trial Results
Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company’s second-quarter earnings report, alongside results from a closely watched trial of its experimental weight-loss pill.
Read MoreLilly Downplaying Obesity Drug Side Effects, Indiana Lawsuits Claim
Lawsuits from at least 26 patients have been filed in Marion County against Eli Lilly and Co. for its marketing of the drugs GLP-1 Trulicity and Mounjaro, claiming the treatments for diabetes and obesity had adverse side effects that the company downplayed or did not mention in advertising.
Read More
Hamilton County Acquires Sheridan Airport Amid Growing Aviation Demand
Hamilton County has finalized the $4.2 million purchase of Sheridan Airport, aiming to accommodate rising demand for private aircraft services across the region.
Read More
Indiana Is Top Life Sciences Exporter, BioCrossroads Report Shows
According to a new BioCrossroads report, in 2024, Indiana was the largest national exporter of life science products and the industry generated $99 billion in economic activity.
Read MoreEU Committee Reject Lilly Alzheimer’s Drug
The European Medicines Agency, citing the potentially dangerous risk of brain swelling and hemorrhage, rejected Eli Lilly and Co.’s new Alzheimer’s disease drug Kisunla.
Read More
Hoosier Companies Appear On “America’s Most Trustworthy” List
Newsweek’s annual list of “Most Trustworthy Companies
in America” has been published, with 13 Hoosier businesses appearing.
Lilly Moves Ahead With $10M Solar Panel Project For Two Indy Corporate Campuses
Eli Lilly and Co. is moving ahead with a $10 million solar panel installation project on their two Indianapolis corporate campuses.
Read MoreLilly Stock Soars, Increasing Profile of City’s Life Sciences District
Over a decade ago, Eli Lilly and Co. was struggling.
Read More
Holcomb Defends Abortion Ban, Rebuffs Talent Attraction Fears
Gov. Eric Holcomb on Wednesday defended his signing of a near-total abortion ban this month and brushed off fears of business and talent attraction consequences in the wake of ominous statements from major homegrown employers.
Read More